Barbital chemical structure
Find information on thousands of medical conditions and prescription drugs.

Barbital

Barbital (marketed under the brand name Veronal), also called barbitone, was the first commercially marketed barbiturate. It was used as a sleeping aid (hypnotic) from 1903 until the mid-1930s. The chemical names for barbital are diethylmalonyl urea or diethylbarbituric acid. Its chemical formula is (C2H5)2C~CO NH]ICO (sodium 5,5-diethyl barbiturate). Veronal was prepared by condensing diethylmalonic ester with urea in the presence of sodium ethylate, or by adding ethyl iodide to the silver salt of malonylurea. more...

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The result was an odorless, slightly bitter, white crystalline powder.

Barbital was first synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering. They published their discovery in 1903 and it was marketed in 1904 by the Bayer company as “Veronal”. A soluble salt of barbital was marketed by the Schering company as “Medinal.” It was dispensed for “insomnia induced by nervous excitability”. It was provided in either capsules or cachets. The therapeutic dose was ten to fifteen grains.

Veronal was considered to be a great improvement over the existing hypnotics. Its taste was slightly bitter, but an improvement over the strong, unpleasant taste of the commonly used bromides. It had few side effects. Its therapeutic dose was far below the toxic dose. However, prolonged usage resulted in tolerance to the drug, requiring higher doses to reach the desired effect. Fatal overdoses of this slow acting hypnotic were not uncommon.

Read more at Wikipedia.org


[List your site here Free!]


HUMAN COMPLEMENT SYSTEM ACTIVATION BY PARACOCCIDIOIDES BRASILIENSIS, IN VITRO
From Revista do Instituto de Medicina Tropical de Sao Paulo, 10/1/05 by Toledo, R G

Toledo, R. G.1; Gomes, G. I.2; Dias da Silva, W.3; Kipnis, T. L.4

1,2,3,4Universidade Estadual do None Fluminense Darcy Ribeiro - Laboratório de Biologia do Reconhecer

Introduction and objectives: The pathogenicity of Paracoccidioides brasiliensis is influenced by its cell wall hexoses (Sabouraudia, 20:31-40, 1982). These carbohydrates are strong candidates for activation of the complement system (CS) particularly the lectin pathway. It's well described that the fungus is capable of activating the alternative pathway, is opsonized by C3 and C4 fragments and augments its ingestion by murine macrophages (Clin. Immunol. Immunopathol., 12:20-30, 1979; J. Med. Vet. MycoL 30:317-321. 1992; J. Med, Vet. Mycol., 30:481-484, 1992). This study aimed to investigate the activation of the alternative, classical and lectin pathways (AP, CP, LP) activation by the fungus, in vitro. Methods: P. brasiliensis yeast forms at concentrations of 10^sup 5^, 10^sup 6^ or 10^sup 7^ cells/mL were incubated with normal human serum (NHS). The total hemolytic activity was assayed by using sheep red erythrocytes (E^sup s^) pre-sensitized with rabbit antibodies anti-E^sup s^ in GVBS buffer (containing 15 mmol/L CaCl^sub 2^, 0.5 mmol/L MgCl^sub 2^, and 1.8 mmol/L sodium barbital), or antibody non sensitized rabbit red erythrocytes in GVBS-MgEGTA (containing 2 mmol/L MgSO^sub 4^, and 10 mmol/L EGTA), to analyze the functional state of the AP and CP complement activation, respectively. The serum levels of the individual components C3, and C4 were immunochemically quantified by ELISA using specific monoclonal antibodies (mAbs) as probes. The LP activation was analyzed by mannose-binding protein (MBL) consumption using mAbs in ELISA. NHS samples treated with buffer or zymosan were included as controls. Results: We observed that P. brasiliensis activates and significantly reduces the hemolytic activity of NHS when AP and CP were analyzed. The fungal action was dose and time dependent. Levels of C3 and C4 in the respective samples were also significantly reduced when compared to the controls. We observed that samples that activated CS (hemolytic assay and ELISA for C3 and C4) had also consumed MBL. Conclusions: These results indicate that P. brasiliensis yeast forms, of the virulent strain Pb18. activate the AP and LP of CS in NHS samples in vitro, and suggest that these pathways may influence fungi/host cell interactions, in vivo. Since either the CP or the LP lead to C4 consumption, MBL-associated serine proteases (MASPs) consumption are now being measured in order to discriminate the participation of both/one pathways. Financial support: UENF, FAPERJ, CNPq

Copyright Instituto de Medicina Tropical de Sao Paulo Oct 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Barbital
Home Contact Resources Exchange Links ebay